Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

NHS funding

NICE recommends osimertinib for inclusion in revamped cancer drugs fund

Carole Longson, director of NICE’s health technology evaluation centre

Source: NICE

Carole Longson, director of NICE’s health technology evaluation centre, says the decision will give patients access to a promising new cancer treatment while more evidence is gathered on its effectiveness

Osimertinib (Tagrisso; AstraZeneca) has become the first new drug to be recommended for inclusion in the revamped cancer drugs fund (CDF) by the National Institute for Health and Care Excellence (NICE).

In draft guidance issued on 4 October 2016, NICE recommends that the drug is funded by the CDF because of promising evidence that it is effective in the long term and represents value for money.

Inclusion in the CDF would allow osimertinib to be used as a managed access product for patients with metastatic EGFR and T790M mutation-positive non-small-cell lung cancer. Its manufacturer would have to continue to provide evidence to support its long-term use and cost effectiveness.

Carole Longson, director of NICE’s health technology evaluation centre, says: “For the first time, we are able to give patients access to a promising new cancer treatment whilst more evidence is gathered on its effectiveness. This is the system working as it should.”

A NICE appraisal committee first considered osimertinib in May 2016. The drug showed early promise but the committee was unconvinced that it was cost effective. Fresh evidence presented by the drug company from ongoing studies and new analysis of existing data has been enough to persuade NICE to make the drug available via the CDF pending its final recommendation.

Between December 2015 and February 2016, the drug was provided free of charge by AstraZeneca after being granted a positive opinion via the government’s early access to medicines scheme (EAMS), which recognises the potential of a medicine to address unmet clinical need.

Its EAMS status was lifted in February 2016 after its conditional marketing authority by the European Medicines Agency was approved by the European Commission following a fast-track assessment.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201790

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Handbook of Drug Administration via Enteral Feeding Tubes

    Handbook of Drug Administration via Enteral Feeding Tubes

    All you need to know about prescribing or administering drugs via enteral feeding tubes. Over 400 drug monographs as well as facts to inform clinical decision making.

    £54.00Buy now
  • Prescribing Medicines for Children

    Prescribing Medicines for Children

    Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.

    £60.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Palliative Care Formulary (PCF6)

    Palliative Care Formulary (PCF6)

    Palliative Care Formulary is a comprehensive combination of independent information about drugs used in palliative care.

    £55.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Carole Longson, director of NICE’s health technology evaluation centre

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.